succinyl-L-Ala-A-Ala-L-Pro-L-Arg-p-nitroanilide | 131068-47-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: succinyl-L-Ala-A-Ala-L-Pro-L-Arg-p-nitroanilide
• 英文别名: Suc-Ala-Ala-Pro-Arg-NH-C6H4-NO2(p)；(2S)-N-[(2S)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]-1-[(2S)-2-[[(2S)-2-(2,5-dioxopyrrolidin-1-yl)propanoyl]amino]propanoyl]pyrrolidine-2-carboxamide
• CAS: 131068-47-8
• 化学式: C₂₇H₃₇N₉O₈
• 分子量: 615.646
• InChiKey: RIIKOVUFQXXKAB-FVCZOJIISA-N

物化性质

• 密度：
  1.50±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  44
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  255
• 氢给体数：
  5
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  Suc-Ala-Ala-Pro-Arg-NH-C6H4-NH2(p) 在 sodium perborate 作用下， 以 溶剂黄146 为溶剂， 反应 18.0h， 生成 succinyl-L-Ala-A-Ala-L-Pro-L-Arg-p-nitroanilide
  参考文献：
  名称：

  Solid phase synthesis of peptide para -nitroanilides

  摘要：

  A facile synthesis of peptide para -nitroanilides was developed using a novel urethane linked para -aminoanilide resin 3 and solid phase peptide synthesis. Conversion of the resulting peptide para -aminoanilides to the corresponding peptide para -nitroanilides was achieved by oxidation with sodium perborate. With the exception of sequences containing methionine, tryptophan and cysteine, all amino acid residues can be used. A representative synthesis of the tetrapeptide para -nitroanilide succinyl-Ala-Ala-Pro-Arg-PNA is described.

  DOI：

  10.1016/s0040-4039(00)77632-5

文献信息

• Substituted phenyl acetamides and their use as protease inhibitors
  申请人：——

  公开号：US20040254166A1

  公开（公告）日：2004-12-16

  Phenyl acetamide compounds are described, including compounds of Formula I: 1 or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R 3 -R 6 , R 11 , B, Y and W are set forth in the specification. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as thrombin and factor Xa. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

  苯乙酰胺化合物的描述，包括式I的化合物： 或其溶剂化合物、水合物或药用可接受盐；其中R 3 -R 6 ，R 11 ，B，Y和W在说明书中列出。本发明的化合物是蛋白酶的强效抑制剂，特别是胰蛋白酶样丝氨酸蛋白酶，如凝血酶和Xa因子。描述了用于抑制血小板丢失、抑制血小板聚集物形成、抑制纤维蛋白形成、抑制血栓形成和抑制栓塞形成的组合物。本发明化合物的其他用途是作为抗凝剂，嵌入或物理连接到用于制造用于血液采集、血液循环和血液储存的设备中的材料中，如导管、血液透析机、血液采集器和管、血管和支架。此外，这些化合物可以被检测标记并用于体内血栓的成像。
• Aminopyridinyl-, aminoguanidinyl- and Alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors
  申请人：3-Dimensional Pharmaceuticals

  公开号：US20020061872A1

  公开（公告）日：2002-05-23

  Phenyl acetamide compounds are described, including compounds of Formula I: 1 or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R 3 -R 6 , R 11 , B, Y and W are set forth in the specification. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as thrombin and factor Xa. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

  苯乙酰胺化合物的描述，包括式I的化合物： 或其溶剂化物、水合物或药学上可接受的盐；其中R 3 -R 6 ，R 11 ，B，Y和W在规范中列出。本发明的化合物是蛋白酶的强效抑制剂，特别是类似胰蛋白酶的丝氨酸蛋白酶，如凝血酶和Xa因子。描述了用于抑制血小板丢失、抑制血小板聚集物形成、抑制纤维蛋白形成、抑制血栓形成和抑制栓塞形成的组合物。本发明化合物的其他用途是作为抗凝剂，嵌入或物理连接到用于制造用于血液采集、血液循环和血液储存的设备中的材料，如导管、血液透析机、血液采集注射器和管、血管和支架。此外，这些化合物可以被检测标记并用于体内血栓的成像。
• Cyclic oxyguanidine protease inhibitors
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20020022615A1

  公开（公告）日：2002-02-21

  Cyclic oxyguanidine compounds, including compounds of Formulae I and II: 1 wherein R 1 , R 3 -R 6 , R 21 -R 26 , L, Y, Z, and A are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formulae I and II. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.

  描述了环氧胍啉化合物，包括式I和II中的化合物：其中规范中列出了R1、R3-R6、R21-R26、L、Y、Z和A，以及其水合物、溶剂合物或药学上可接受的盐，这些化合物抑制蛋白酶酶，如凝血酶。还描述了制备式I和II化合物的方法。本发明的新化合物是蛋白酶的有效抑制剂，尤其是胰蛋白酶样丝氨酸蛋白酶，如胰蛋白酶、凝血酶、纤溶酶和Xa因子。某些化合物通过直接、选择性抑制凝血酶表现出抗血栓活性，或者是用于形成具有抗血栓活性的化合物的中间体。该发明包括一种用于抑制哺乳动物体内血小板丧失、抑制血小板集合体形成、抑制纤维蛋白形成、抑制血栓形成和抑制栓塞形成的组合物，包括本发明的化合物在药学上可接受的载体中。本发明的化合物的其他用途是作为抗凝剂，嵌入或物理连接到用于血液收集、血液循环和血液储存设备的材料中，如导管、血液透析机、血液收集器和管、血管和支架。
• Cyclic oxyguanidine pyrazinones as protease inhibitors
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20020052357A1

  公开（公告）日：2002-05-02

  Cyclic oxyguanidine pyrazinone compounds are described, including compounds of the Formula I: 1 wherein R 3 , R 4 , R 5 , W, and A are as set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

  本文描述了环状氧胍吡唑酮化合物，包括公式I中的化合物：其中R3、R4、R5、W和A如规范中所述，以及其水合物、溶剂化物或药学上可接受的盐。本发明的化合物是蛋白酶的有效抑制剂，特别是胰蛋白酶样丝氨酸蛋白酶，如凝血酶、胰蛋白酶、血栓素、纤溶酶和Xa因子。其中某些化合物通过直接选择性抑制凝血酶表现出抗血栓活性。本文还描述了用于抑制血小板丢失、抑制血小板聚集形成、抑制纤维蛋白形成、抑制血栓形成和抑制栓塞形成的组合物。本发明化合物的其他用途是作为抗凝剂嵌入或物理连接到用于血液收集、血液循环和血液储存的器械制造材料中，例如导管、血液透析机、血液采集注射器和管道、血管支架。此外，这些化合物可以被检测标记并用于体内血栓的成像。
• [EN] HETEROARYL PROTEASE INHIBITORS AND DIAGNOSTIC IMAGING AGENTS<br/>[FR] INHIBITEURS DE PROTEASE HETEROARYLE ET AGENTS D'IMAGERIE DIAGNOSTIQUE
  申请人：DIMENSIONAL PHARM INC

  公开号：WO2001004117A1

  公开（公告）日：2001-01-18

  Ketothiazole alkoxyguanidine and aminoguanidine analogs are described, including compounds of formula (I) wherein X is O or NR9 and Het, A, R?1, R7, R8, R12, R13, Ra, Rb, Rc¿, Z, m and n are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin. Also described are methods for preparing such compounds. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

  本发明涉及Ketothiazole alkoxyguanidine和aminoguanidine类似物，包括式（I）中的化合物，其中X为O或NR9，Het，A，R？1，R7，R8，R12，R13，Ra，Rb，Rc¿，Z，m和n在说明书中阐述，以及其水合物，溶剂化物或药学上可接受的盐，用于抑制蛋白酶酶，如凝血酶。还描述了制备这种化合物的方法。本发明的化合物是蛋白酶的有效抑制剂，特别是类似胰蛋白酶的丝氨酸蛋白酶，如胰蛋白酶，凝血酶，纤溶酶和Xa因子。其中某些化合物通过直接选择性抑制凝血酶表现出抗血栓作用。本发明包括一种用于抑制哺乳动物中的血小板丢失，抑制血小板聚集的形成，抑制纤维蛋白形成，抑制血栓形成和抑制栓塞形成的组合物，其中包括本发明的化合物和药学上可接受的载体。本发明的化合物的其他用途是作为抗凝剂，嵌入或物理连接到用于血液收集，血液循环和血液储存的设备中使用的材料中，例如导管，血液透析机，血液收集注射器和管道，血液管路和支架。此外，这些化合物可以被检测标记并用于体内血栓成像。